IASO Bio Announces NMPA IND Approval for IASO208, Advancing Its In Vivo CAR-T Platform into Synchronized U.S.-China Clinical Development
IASO Bio received NMPA IND approval for its in vivo CAR-T product known as IASO208. This marks the first lentiviral-vector-based product from China to also get U.S. FDA IND clearance. The company is moving toward synchronized clinical development in both the United States and China. A Phase Ib study focusing on R/R B-NHL will start directly in the United States. The company is a commercial-stage biopharmaceutical firm based in Shanghai, Nanjing, and Pleasanton.
First lentiviral-vector-based in vivo CAR-T product from China to receive a U.S. FDA IND clearance; a Phase Ib study in R/R B-NHL will be initiated directly in the United States SHANGHAI, NANJING, China, and PLEASANTON, Calif., Nov. 10, 2026 /PRNewswire/ — IASO Biotechnology (“IASO Bio”), a commercial-stage biopharmaceutical company focused on the discovery, development, manufacturing, and […]